Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have access to a participating site and are willing to be followed for the duration of the study~* Willing to receive HIV test results~* Able to understand and comply with study requirements~* In good general health~* Have neutralizing adenovirus antibody levels that are less than a 1:12 ratio~* Agree to use acceptable methods of contraception for at least 21 days prior to study start and for the duration of the study.~Exclusion Criteria:~* HIV infected~* Positive hepatitis B surface antigen~* Positive anti-hepatitis C virus antibodies~* Prior receipt of an HIV vaccine~* Immunosuppressive drugs within 168 days prior to first vaccination~* Have received donated blood within 120 days prior to first vaccination~* Have received immunoglobulin within 60 days of the first vaccination~* Live attenuated vaccines or investigational research agents within 30 days prior to first vaccination~* Subunit or killed vaccines within 14 days prior to first vaccination~* Current preventive or therapeutic anti-tuberculosis (TB) treatment~* Any medical, psychiatric, or social condition that would interfere with the study~* Any occupational or other responsibility that would interfere with the study~* Serious adverse reactions to vaccines~* Autoimmune disease~* Immunodeficiency~* Active syphilis infection. Participants who have been fully treated for syphilis over 6 months prior to study entry are not excluded.~* Asthma. Participants who have had completely resolved childhood asthma are not excluded.~* Diabetes mellitus type I or II. Participants who have had isolated gestational diabetes are not excluded.~* Thyroid disease or removal of the thyroid~* Blood vessel swelling within the last 3 years~* Uncontrolled hypertension~* Body mass index (BMI) of 40 or higher~* Bleeding disorder~* Cancer. Participants whose cancer has been removed and is unlikely to recur during the study are not excluded.~* Seizure disorder. Participants who have not required medication or had a seizure for 3 years prior to study entry are not excluded.~* Removal of the spleen or have a nonfunctioning spleen~* Psychiatric conditions that may interfere with the study~* Pregnancy, breastfeeding, or plan to become pregnant during the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).